Francisco Silva - 12 Oct 2022 Form 4 Insider Report for BioRestorative Therapies, Inc. (BRTX)

Role: VP of Research and Development, Director
Signature: /s/ Francisco Silva
Issuer symbol: BRTX
Transactions as of: 12 Oct 2022
Net transactions value: +$2,457
Form type: 4
Filing time: 12 Oct 2022, 14:01:11 UTC
Previous filing: 12 Oct 2022
Next filing: 04 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BRTX	Common Stock	Purchase	$2,457	+725	+0.44%	$3.39	165,103	12 Oct 2022	Direct	F1
holding	BRTX	Common Stock						12,136	12 Oct 2022	IRA

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BRTX	Stock Option						1	12 Oct 2022	Common Stock	1	$3000.00	Direct	F2
holding	BRTX	Stock Option						1	12 Oct 2022	Common Stock	1	$3000.00	Direct	F2
holding	BRTX	Stock Option						3	12 Oct 2022	Common Stock	3	$3000.00	Direct	F2
holding	BRTX	Stock Option						1	12 Oct 2022	Common Stock	1	$3000.00	Direct
holding	BRTX	Stock Option						9	12 Oct 2022	Common Stock	9	$3000.00	Direct	F2
holding	BRTX	Stock Option						6	12 Oct 2022	Common Stock	6	$3000.00	Direct	F2
holding	BRTX	Stock Option						15	12 Oct 2022	Common Stock	15	$3000.00	Direct	F2
holding	BRTX	Stock Option						20	12 Oct 2022	Common Stock	20	$3000.00	Direct	F2
holding	BRTX	Stock Option						25	12 Oct 2022	Common Stock	25	$3000.00	Direct	F2
holding	BRTX	Stock Option						293,479	12 Oct 2022	Common Stock	293,479	$13.50	Direct	F3
holding	BRTX	Stock Option						42,059	12 Oct 2022	Common Stock	42,059	$13.50	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on each of November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.
F2	The option is currently exercisable.
F3	The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.
F4	The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.